CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on December 18, 2015
|
|
Seaport West
617 832 1000 main 617 832 7000 fax |
| December 18, 2015 | |
| VIA EDGAR | |
|
Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549
|
||||
| Re: |
Cellectar Biosciences, Inc. (CIK 0001279704) Registration Statement on Form S-1 |
|||
Ladies and Gentlemen:
This letter constitutes supplemental correspondence on behalf of Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), related to and filed together with the Company’s Registration Statement on Form S-1 (the “Registration Statement”). The Registration Statement covers the issuance and sale by the Company of shares of the Company’s common stock, $0.00001 par value per share (“Common Stock”), and warrants to purchase shares of Common Stock (the “Warrants”), together in an underwritten offering intended to raise $10,000,000.
Please direct any communications concerning the Registration Statement to the undersigned at (617) 832-1113, email—pbork@foleyhoag.com, or, in my absence, Daniel Clevenger at (617) 832-1283, email—dclevenger@foleyhoag.com. The email address of the Company’s agent for service is jcaruso@cellectar.com.
| Very truly yours, | |||
| /s/ | Paul Bork | ||
| Paul Bork | |||
| cc: | Daniel Clevenger, Esq. |
| ATTORNEYS AT LAW | BOSTON | NEW YORK | PARIS | WASHINGTON | FOLEYHOAG.COM |